Technical Analysis for LGND - Ligand Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade F 117.9 6.48% 7.18
LGND closed up 6.48 percent on Friday, January 18, 2019, on 1.67 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical LGND trend table...

Date Alert Name Type % Chg
Jan 18 Lower Bollinger Band Walk Weakness 0.00%
Jan 18 Multiple of Ten Bearish Other 0.00%
Jan 18 Multiple of Ten Bullish Other 0.00%
Jan 18 Lower Bollinger Band Touch Weakness 0.00%
Jan 17 New Downtrend Bearish 6.48%
Jan 17 Jack-in-the-Box Bearish Bearish Swing Setup 6.48%
Jan 17 Calm After Storm Range Contraction 6.48%
Jan 17 Lower Bollinger Band Walk Weakness 6.48%
Jan 17 Multiple of Ten Bullish Other 6.48%
Jan 17 Inside Day Range Contraction 6.48%

Older signals for LGND ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company's assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company's late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.
Is LGND a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 278.62
52 Week Low 98.56
Average Volume 776,846
200-Day Moving Average 193.3103
50-Day Moving Average 143.7202
20-Day Moving Average 132.2395
10-Day Moving Average 129.43
Average True Range 9.1868
ADX 29.19
+DI 11.5777
-DI 35.0643
Chandelier Exit (Long, 3 ATRs ) 117.3896
Chandelier Exit (Short, 3 ATRs ) 126.1204
Upper Bollinger Band 150.2525
Lower Bollinger Band 114.2265
Percent B (%b) 0.1
BandWidth 27.242995
MACD Line -7.5909
MACD Signal Line -5.9755
MACD Histogram -1.6154
Fundamentals Value
Market Cap 2.48 Billion
Num Shares 21.1 Million
EPS 0.41
Price-to-Earnings (P/E) Ratio 287.56
Price-to-Sales 25.74
Price-to-Book 7.36
PEG Ratio 1.53
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 134.02
Resistance 3 (R3) 133.15 126.90 131.33
Resistance 2 (R2) 126.90 122.80 127.34 130.44
Resistance 1 (R1) 122.40 120.26 124.65 123.27 129.54
Pivot Point 116.16 116.16 117.28 116.59 116.16
Support 1 (S1) 111.66 112.05 113.91 112.53 106.26
Support 2 (S2) 105.41 109.51 105.85 105.36
Support 3 (S3) 100.91 105.41 104.47
Support 4 (S4) 101.78